박용욱 교수 연구실
article|
gold
·인용수 101
·2022
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial
Joon Young Song, Won Suk Choi, Jung Yeon Heo, Jin Soo Lee, Dong Sik Jung, Shin‐Woo Kim, Kyung‐Hwa Park, Joong Sik Eom, Su Jin Jeong, Jacob Lee, Ki Tae Kwon, Hee Jung Choi, Jang Wook Sohn, Young Keun Kim, Ji Yun Noh, Woo Joo Kim, François Roman, Maria Angeles Ceregido, Francesca Solmi, Agathe Philippot, Alexandra C. Walls, Lauren Carter, David Veesler, Neil P. King, Hun Kim, Ji Hwa Ryu, Su Jeen Lee, Yong Wook Park, Ho Keun Park, Hee Jin Cheong
EClinicalMedicine
초록
This work was supported, in whole or in part, by funding from CEPI and the Bill & Melinda Gates Foundation Investment ID OPP1148601. The Bill & Melinda Gates Foundation supported this project for the generation of IND-enabling data and CEPI supported this clinical study.
키워드
MedicineImmunogenicityVaccinationPlaceboRandomized controlled trialInternal medicineImmunologyAntibodyAlternative medicinePathology